CRM197 (nontoxic diphtheria toxin): Effects on advanced cancer patients

Cancer Immunology, Immunotherapy

Volumn 53, Issue 11, 2004, Pages 1041-1048

  Buzzi, Silvio ^a   Rubboli, Diego ^b   Buzzi, Giorgio ^a   Buzzi, Anna Maria ^a   Morisi, Claudio ^b   Pironi, Flavio ^b  

^a Tris Medical Center   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Antitumor activity; Clinical trial; Nontoxic diphtheria toxin

Indexed keywords

CROSS REACTING MATERIAL 197; DIPHTHERIA TOXIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MEMBRANE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOREACTIVITY; INFLAMMATION; MALE; MYALGIA; NEUROBLASTOMA; NEUTROPHIL; OUTPATIENT; PRIORITY JOURNAL; SKIN IRRITATION;

AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; CELL LINE, TUMOR; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FEMALE; HEPARIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5644239687     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0546-4     Document Type: Article

References (19)

1. Pappenheimer AM Jr (1977) Diphtheria toxin. Ann Rev Biochem 46:69
2. Rappuoli R (1990) New and improved vaccines against diphtheria and tetanus: In: WoodrowGC, Levine MM (eds) New generation vaccines. Marcel Dekker, New York, p 251
3. Raab G, Klagsbrun M (1997) Heparin-binding EGF-like growth factor. BiochimBiophysActa 1333:179
4. Buzzi S, Maistrello I (1973) Inhibition of growth of Ehrlich tumors in Swiss mice by diphtheria toxin. Cancer Res 33:2349
5. Buzzi S (1982) Diphtheria toxin treatment of human advanced cancer. Cancer Res 42:2054
6. Buzzi S, Buzzi L (1974) Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin. Cancer Res 34:3481
7. Buzzi S (1974) Diphtheria toxin in cancer therapy. Lancet 1:628
8. Buzzi S, Baccini C, Rubboli D, Monti G, Buzzi G, Buzzi AM (1999) Phase I-II study of CRM197 administration to 50 advanced cancer patients. AACR.NCI.EORTC Inter Conf abstract 384
9. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F (2002) CRM197: phagocyte mediated antitumor activity followed by a connective proliferation tending to encapsule the tumor. Proc AACR (Abstract 4529)
10. Harnisch JP (1980) Diphtheria. In: Isselbacher KJ, Adams RD, Braunwald E, Petersdorf RG, Wilson JD (eds) Harrison's principles of internal medicine. McGraw-Hill, New York, p 671
11. Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, Wood WB (1968) Microbiology. Harper & Row, New York, p 676
12. Wirtz M, Puccinelli M, Mele C, Gentili G (1995) Immunity to diphtheria in the 4-70 year age group in Italy. Vaccine 13:771
13. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
14. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405
15. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, Larkin EW, Holbrook CT, Silverman JF, Norris HT, Hayes FA, Smith EI, Castleberry RP (1993) Correlation between morphologic and other prognostic markers of neuroblastoma. Cancer 71:3173
16. Aggarwal BB (2000) Tumor necrosis factor (TNF): a double-edged sword. J Clin Ligand Assay 23:181
17. Roberts WG, Palade GE (1997) Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57:765
18. Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365
19. Oberley LW, Buettner GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Res 39:1141